Company intelligence / Profile preview

Magdalena Biosciences

Dover, Delaware, United Statesmagdalenabiosciences.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Magdalena’s lead candidate MB2500 has shown statistically significant efficacy in animal models of depression, anxiety, and cognitive deficit. PET scan data indicate increased neuronal activity in the prefrontal cortex with improved brain connectivity. The company aims to file its first IND in 2025 targeting executive dysfunction in ADHD or cognitive deficit in schizophrenia. Additional programs are at the preclinical stage targeting other mental health indications

Therapeutic areas: Psychiatry
Modalities: Botanical drugs (plant-derived small molecules and extracts)
Industry: Biotech

Drug pipeline

2 assets

MB2500

Preclinical

1 more asset in the full pipeline.

Partnerships

Joint venture between Jaguar Health and Filament Health Corp.

Beyond the preview

Go deeper on Magdalena Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Magdalena Biosciences.